

In the Claims:

Please amend the claims as follows:

1. (original) A phosphate derivative of a compound selected from the group consisting of pravastatin and derivatives thereof, atorvastatin and derivatives thereof, venlafaxine and derivatives thereof and mixtures thereof.

2. (original) The phosphate derivative according to claim 1 wherein the phosphate derivative is a phosphatide.

3. (original) The phosphate derivative according to claim 1 wherein the phosphate derivative is a complex, the complexing agent being selected from the group consisting of amphoteric surfactants, cationic surfactants, amino acids having nitrogen functional groups and proteins rich in these amino acids, and mixtures thereof.

4. (original) The phosphate derivative according to claim 3 wherein the complexing agent is selected from the group consisting of glycine, arginine, lysine, histidine and lauryl- imino-dipropionate.

5. (original) A method for phosphorylating a compound having a secondary hydroxy group comprising step (a) reacting the compound having a secondary hydroxy group with P_4O_{10} in the presence of an alkali

metal salt of a fatty acid.

6. (original) The method according to claim 5 wherein the compound having a secondary hydroxy group is selected from the group consisting of pravastatin, atorvastatin or venlafaxine.

7. (original) The method according to claim 5 wherein the alkali metal salt of a fatty acid is sodium valerate.

8. (original) The method according to claim 5 further comprising step (b) reacting the product of step (a) with a di or mono acyl glyceride to form a phosphatide.

9. (original) The method according to claim 5 further comprising step (b') reacting the product of step (a) with a complexing agent is selected from the group comprising amphoteric surfactants, cationic surfactants, amino acids having nitrogen functional groups and proteins rich in these amino acids.

10. (original) The method according to claim 8 further comprising step (c) reacting the product of step (b) with a complexing agent is selected from the group comprising amphoteric surfactants, cationic surfactants, amino acids having nitrogen functional groups and proteins rich in these amino acids.

11. (currently amended) The method according to ~~either of claims 9 or 10~~ claim 9 wherein the complexing agent is selected from the group consisting of glycine, arginine, lysine, histidine and lauryl- imino-dipropionate.

12. (original) A phosphate derivative comprising the reaction product of a compound having a secondary hydroxy group reacted with P_4O_{10} in the presence of an alkali metal salt of a fatty acid.

13. (original) A phosphate derivative selected from the group consisting of [R-(R*,R*)]-2-(4-fluorophenyl)- β -phosphono- δ -hydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-*lH*-pyrrole-1-heptanoic acid, [1S-[1 α (β S*, δ S*),2 α ,6 α ,8 β (R*),8 $\alpha\alpha$]]-1,2,6,7,8,8a-hexahydro- β -phosphono- δ ,6-dihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-1-naphthleneheptanoic acid, 1-[-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexyl dihydrogen phosphate and mixtures thereof.

14. (original) A phosphate derivative selected from the group consisting of 1,2-distearoyl phosphatidyl atorvastatin, 1,2-distearoyl phosphatidyl pravastatin, 1,2-distearoyl phosphatidyl venlafaxine and mixtures thereof.

15. (currently amended) A phosphate derivative according to ~~any one of claims 1 to 3 or 12 to 14~~ claim 1 when administered to a patient to lower patient serum cholesterol levels.

16. (currently amended) A phosphate derivative according to ~~any one of claims 1 to 3 or 12 to 14~~ claim 1 when administered to a patient to treat depression.

17. (new) The method according to claim 10 wherein the complexing agent is selected from the group consisting of glycine, arginine, lysine, histidine and lauryl- imino-dipropionate.

18. (new) A phosphate derivative according to claim 12 when administered to a patient to lower patient serum cholesterol levels.

19. (new) A phosphate derivative according to claim 13 when administered to a patient to lower patient serum cholesterol levels.

20. (new) A phosphate derivative according to claim 14 when administered to a patient to lower patient serum cholesterol levels.

21. (new) A phosphate derivative according to claim 12 when administered to a patient to treat depression.